Loading
London oncologist who helped develop abiraterone and led the STAMPEDE analysis showing that two years of abiraterone alongside hormone therapy and radiotherapy improves survival in high-risk localised prostate cancer.
Gerhardt Attard is a medical oncologist at the UCL Cancer Institute who worked on the early clinical development of abiraterone at The Institute of Cancer Research. He was first author of the 2022 Lancet report of the STAMPEDE platform's combined analysis, which showed that adding abiraterone (with or without enzalutamide) to androgen deprivation therapy improved metastasis-free and overall survival in high-risk non-metastatic prostate cancer. His laboratory studies androgen receptor genomics and plasma DNA in prostate cancer.
Two years of abiraterone with androgen deprivation and radiotherapy is the standard for very high-risk and node-positive localised prostate cancer.
The proof, in people, that castration-resistant prostate cancer is usually still androgen-driven. It renamed the disease (hormone-refractory became castration-resistant) and it opened the line of drugs that now dominate treatment at every stage from first diagnosis of metastatic disease onwards.
Shares Prostate cancer and the tags prostate, trialist.
Shares Prostate cancer and the tags prostate, trialist.
Shares Prostate cancer and the tags prostate, trialist.
Shares Prostate cancer and the tags prostate, trialist.
Shares Localised prostate cancer, high and very high risk, Prostate cancer and the tags prostate, trialist.
Shares Prostate cancer and the tags prostate, trialist.
Shares Prostate cancer and the tags prostate, trialist.
Shares Prostate cancer and the tags prostate, trialist.